GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Harmony Biosciences Holdings Inc (NAS:HRMY) » Definitions » Enterprise Value

Harmony Biosciences Holdings (Harmony Biosciences Holdings) Enterprise Value : $1,549.8 Mil (As of Jun. 08, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Harmony Biosciences Holdings Enterprise Value?

Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Harmony Biosciences Holdings's Enterprise Value is $1,549.8 Mil. Harmony Biosciences Holdings's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was $213.0 Mil. Therefore, Harmony Biosciences Holdings's EV-to-EBIT ratio for today is 7.27.

EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Harmony Biosciences Holdings's Enterprise Value is $1,549.8 Mil. Harmony Biosciences Holdings's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 was $237.5 Mil. Therefore, Harmony Biosciences Holdings's EV-to-EBITDA ratio for today is 6.53.

EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Harmony Biosciences Holdings's Enterprise Value is $1,549.8 Mil. Harmony Biosciences Holdings's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was $617.5 Mil. Therefore, Harmony Biosciences Holdings's EV-to-Revenue ratio for today is 2.51.


Harmony Biosciences Holdings Enterprise Value Historical Data

The historical data trend for Harmony Biosciences Holdings's Enterprise Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Harmony Biosciences Holdings Enterprise Value Chart

Harmony Biosciences Holdings Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Enterprise Value
Get a 7-Day Free Trial - 2,022.21 2,466.01 3,153.36 1,673.75

Harmony Biosciences Holdings Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Enterprise Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,805.20 1,931.89 1,745.86 1,673.75 1,724.69

Competitive Comparison of Harmony Biosciences Holdings's Enterprise Value

For the Biotechnology subindustry, Harmony Biosciences Holdings's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Harmony Biosciences Holdings's Enterprise Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Harmony Biosciences Holdings's Enterprise Value distribution charts can be found below:

* The bar in red indicates where Harmony Biosciences Holdings's Enterprise Value falls into.



Harmony Biosciences Holdings Enterprise Value Calculation

Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

Harmony Biosciences Holdings's Enterprise Value for the fiscal year that ended in Dec. 2023 is calculated as

Harmony Biosciences Holdings's Enterprise Value for the quarter that ended in Mar. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Harmony Biosciences Holdings  (NAS:HRMY) Enterprise Value Explanation

When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.

If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.

The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.

For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.

Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.

1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.

Harmony Biosciences Holdings's EV-to-EBIT for today is

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=1549.798/213.048
=7.27

Harmony Biosciences Holdings's current Enterprise Value is $1,549.8 Mil.
Harmony Biosciences Holdings's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $213.0 Mil.

2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.

Harmony Biosciences Holdings's EV-to-EBITDA for today is:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA(TTM)
=1549.798/237.467
=6.53

Harmony Biosciences Holdings's current Enterprise Value is $1,549.8 Mil.
Harmony Biosciences Holdings's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $237.5 Mil.

3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.

Harmony Biosciences Holdings's EV-to-Revenue for today is:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=1549.798/617.511
=2.51

Harmony Biosciences Holdings's current Enterprise Value is $1,549.8 Mil.
Harmony Biosciences Holdings's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $617.5 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Harmony Biosciences Holdings Enterprise Value Related Terms

Thank you for viewing the detailed overview of Harmony Biosciences Holdings's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Harmony Biosciences Holdings (Harmony Biosciences Holdings) Business Description

Traded in Other Exchanges
N/A
Address
630 West Germantown Pike, Suite 215, Plymouth Meeting, PA, USA, 19462
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant), is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and used for the treatment of cataplexy in adult patients with narcolepsy.
Executives
Peter Anastasiou director C/O HARMONY BIOSCIENCES HOLDINGS, INC., 630 W. GERMANTOWN PIKE, SUITE 215, PLYMOUTH MEETING PA 19462
Jack Nielsen director C/O AKEBIA THERAPEUTICS, INC., 245 FIRST STREET, SUITE 1100, CAMBRIDGE MA 02142
Andreas Wicki director C/O HBM BIOVENTURES (CAYMAN) LTD., CENTENNIAL TOWERS,STE.305,2454 W.BAY RD., GRAND CAYMAN E9 E9
Andrew Serafin officer: Chief Business Officer 630 W. GERMANTOWN PIKE, PLYMOUTH MEETING PA 19462
Jeffrey M. Dayno officer: Chief Medical Officer 460 EAST SWEDESFORD ROAD, SUITE 1050, WAYNE PA 19087
Jeffrey Dierks officer: Chief Commercial Officer 630 W. GERMANTOWN PIKE, SUITE 215, PLYMOUTH MEETING PA 19462
John C Jacobs director, officer: President, CEO 630 W. GERMANTOWN PIKE, SUITE 215, PLYMOUTH MEETING PA 19462
Linda M Szyper director C/O NEOS THERAPEUTICS, INC., 2940 N. HIGHWAY 250, SUITE 400, GRAND PRAIRIE TX 75050
Sandip Kapadia officer: Chief Financial Officer 450 WEST 15 STREET, SUITE 505, NEW YORK NY 10011
R. Mark Graf director C/O DISCOVER FINANCIAL SERVICES, 2500 LAKE COOK ROAD, RIVERWOODS IL 60015
Eric L Motley director 1516 33RD STREET NW, WASHINGTON DC 20007
Valor Equity Partners Iv-a L.p. 10 percent owner 875 NORTH MICHIGAN AVENUE, SUITE 3214, CHICAGO IL 60611
Valor Equity Partners Iv-b L.p. 10 percent owner 875 NORTH MICHIGAN AVENUE, SUITE 3214, CHICAGO IL 60611
Marshman Fund Trust Ii 10 percent owner 630 W. GERMANTOWN PIKE, SUITE 215, PLYMOUTH MEETING PA 19462
Valor Equity Capital Iv Llc 10 percent owner 875 N. MICHIGAN AVENUE, SUITE 3214, CHICAGO IL 60611